The global atopic dermatitis clinical trials market size is calculated at USD 3.04 billion in 2025 and is forecasted to reach around USD 7.73 billion by 2034, accelerating at a CAGR of 10.97% from 2025 to 2034. The North America atopic dermatitis clinical trials market size surpassed USD 1.01 billion in 2024 and is expanding at a CAGR of 11.12% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Atopic Dermatitis Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Atopic Dermatitis Clinical Trials Market, by Molecule Type
8.1.1 Small Molecules
8.1.1.1. Market Revenue and Forecast
8.1.2. Large Molecules
8.1.2.1. Market Revenue and Forecast
9.1. Atopic Dermatitis Clinical Trials Market, by Study Design
9.1.1. Interventional
9.1.1.1. Market Revenue and Forecast
9.1.2. Observational
9.1.2.1. Market Revenue and Forecast
10.1. Atopic Dermatitis Clinical Trials Market, by Phase
10.1.1. Phase I
10.1.1.1. Market Revenue and Forecast
10.1.2. Phase II
10.1.2.1. Market Revenue and Forecast
10.1.3. Phase III
10.1.3.1. Market Revenue and Forecast
10.1.4. Phase IV
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Molecule Type
11.1.2. Market Revenue and Forecast, by Study Design
11.1.3. Market Revenue and Forecast, by Phase
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Molecule Type
11.1.4.2. Market Revenue and Forecast, by Study Design
11.1.4.3. Market Revenue and Forecast, by Phase
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Molecule Type
11.1.5.2. Market Revenue and Forecast, by Study Design
11.1.5.3. Market Revenue and Forecast, by Phase
11.2. Europe
11.2.1. Market Revenue and Forecast, by Molecule Type
11.2.2. Market Revenue and Forecast, by Study Design
11.2.3. Market Revenue and Forecast, by Phase
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Molecule Type
11.2.4.2. Market Revenue and Forecast, by Study Design
11.2.4.3. Market Revenue and Forecast, by Phase
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Molecule Type
11.2.5.2. Market Revenue and Forecast, by Study Design
11.2.5.3. Market Revenue and Forecast, by Phase
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Molecule Type
11.2.6.2. Market Revenue and Forecast, by Study Design
11.2.6.3. Market Revenue and Forecast, by Phase
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Molecule Type
11.2.7.2. Market Revenue and Forecast, by Study Design
11.2.7.3. Market Revenue and Forecast, by Phase
11.3. APAC
11.3.1. Market Revenue and Forecast, by Molecule Type
11.3.2. Market Revenue and Forecast, by Study Design
11.3.3. Market Revenue and Forecast, by Phase
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Molecule Type
11.3.4.2. Market Revenue and Forecast, by Study Design
11.3.4.3. Market Revenue and Forecast, by Phase
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Molecule Type
11.3.5.2. Market Revenue and Forecast, by Study Design
11.3.5.3. Market Revenue and Forecast, by Phase
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Molecule Type
11.3.6.2. Market Revenue and Forecast, by Study Design
11.3.6.3. Market Revenue and Forecast, by Phase
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Molecule Type
11.3.7.2. Market Revenue and Forecast, by Study Design
11.3.7.3. Market Revenue and Forecast, by Phase
11.4. MEA
11.4.1. Market Revenue and Forecast, by Molecule Type
11.4.2. Market Revenue and Forecast, by Study Design
11.4.3. Market Revenue and Forecast, by Phase
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Molecule Type
11.4.4.2. Market Revenue and Forecast, by Study Design
11.4.4.3. Market Revenue and Forecast, by Phase
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Molecule Type
11.4.5.2. Market Revenue and Forecast, by Study Design
11.4.5.3. Market Revenue and Forecast, by Phase
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Molecule Type
11.4.6.2. Market Revenue and Forecast, by Study Design
11.4.6.3. Market Revenue and Forecast, by Phase
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Molecule Type
11.4.7.2. Market Revenue and Forecast, by Study Design
11.4.7.3. Market Revenue and Forecast, by Phase
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Molecule Type
11.5.2. Market Revenue and Forecast, by Study Design
11.5.3. Market Revenue and Forecast, by Phase
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Molecule Type
11.5.4.2. Market Revenue and Forecast, by Study Design
11.5.4.3. Market Revenue and Forecast, by Phase
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Molecule Type
11.5.5.2. Market Revenue and Forecast, by Study Design
11.5.5.3. Market Revenue and Forecast, by Phase
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sanofi SA
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Regeneron Pharmaceuticals, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AbbVie Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis International AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Eli Lilly and Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. GlaxoSmithKline plc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Johnson & Johnson
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Leo Pharma A/S
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Dermira, Inc. (acquired by Eli Lilly and Company)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample